Multibax Past Earnings Performance
Past criteria checks 1/6
Multibax's earnings have been declining at an average annual rate of -28.2%, while the Chemicals industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 3.9% per year. Multibax's return on equity is 2.3%, and it has net margins of 0.8%.
Key information
-28.2%
Earnings growth rate
-28.2%
EPS growth rate
| Chemicals Industry Growth | 8.0% |
| Revenue growth rate | -3.9% |
| Return on equity | 2.3% |
| Net Margin | 0.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Multibax makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,308 | 11 | 82 | 0 |
| 30 Jun 24 | 1,244 | 23 | 82 | 0 |
| 31 Mar 24 | 1,143 | -4 | 84 | 0 |
| 31 Dec 23 | 1,119 | -38 | 86 | 0 |
| 30 Sep 23 | 1,282 | -62 | 100 | 0 |
| 30 Jun 23 | 1,601 | 11 | 107 | 0 |
| 31 Mar 23 | 1,878 | 74 | 110 | 0 |
| 31 Dec 22 | 1,972 | 123 | 111 | 0 |
| 30 Sep 22 | 1,890 | 166 | 107 | 0 |
| 30 Jun 22 | 1,731 | 133 | 100 | 0 |
| 31 Mar 22 | 1,515 | 89 | 101 | 0 |
| 31 Dec 21 | 1,460 | 62 | 101 | 0 |
| 30 Sep 21 | 1,463 | 41 | 99 | 0 |
| 30 Jun 21 | 1,574 | 65 | 103 | 0 |
| 31 Mar 21 | 1,795 | 134 | 107 | 0 |
| 31 Dec 20 | 1,883 | 176 | 107 | 0 |
| 30 Sep 20 | 1,891 | 182 | 105 | 0 |
| 30 Jun 20 | 1,678 | 126 | 106 | 0 |
| 31 Mar 20 | 1,504 | 69 | 105 | 0 |
| 31 Dec 19 | 1,436 | 51 | 105 | 0 |
| 30 Sep 19 | 1,381 | 45 | 107 | 0 |
| 30 Jun 19 | 1,470 | 81 | 105 | 0 |
| 31 Mar 19 | 1,548 | 94 | 100 | 0 |
| 31 Dec 18 | 1,561 | 83 | 103 | 0 |
| 30 Sep 18 | 1,634 | 79 | 101 | 0 |
| 30 Jun 18 | 1,627 | 53 | 102 | 0 |
| 31 Mar 18 | 1,646 | 49 | 100 | 0 |
| 31 Dec 17 | 1,654 | 61 | 100 | 0 |
| 30 Sep 17 | 1,629 | 60 | 97 | 0 |
| 30 Jun 17 | 1,599 | 69 | 94 | 0 |
| 31 Mar 17 | 1,521 | 57 | 93 | 0 |
| 31 Dec 16 | 1,525 | 58 | 88 | 0 |
| 30 Sep 16 | 1,541 | 68 | 88 | 0 |
| 30 Jun 16 | 1,613 | 69 | 89 | 0 |
| 31 Mar 16 | 1,683 | 86 | 89 | 0 |
| 31 Dec 15 | 1,729 | 76 | 90 | 0 |
| 30 Sep 15 | 1,772 | 58 | 92 | 0 |
| 30 Jun 15 | 1,771 | 45 | 93 | 0 |
| 31 Mar 15 | 1,770 | 33 | 93 | 0 |
| 31 Dec 14 | 1,748 | 42 | 94 | 0 |
| 30 Sep 14 | 1,698 | 48 | 92 | 0 |
| 30 Jun 14 | 1,624 | 43 | 91 | 0 |
| 31 Mar 14 | 1,542 | 9 | 91 | 0 |
| 31 Dec 13 | 1,465 | 10 | 90 | 0 |
Quality Earnings: MBAX-R has a large one-off gain of THB10.6M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: MBAX-R became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MBAX-R's earnings have declined by 28.2% per year over the past 5 years.
Accelerating Growth: MBAX-R has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MBAX-R has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (28.8%).
Return on Equity
High ROE: MBAX-R's Return on Equity (2.3%) is considered low.